This is a key and critical role within our organization and this should be reflected in the responsibilities for this position. As the Program Head for IMU-838, you will coordinate and steer all of the development and pre-registration activities throughout all of the different departments for Vidofludimus Calcium, our most advanced development candidate in Phase 3 trials for Relapsing MS and in Phase 2 trials for Progressive MS. You will leverage your extensive experience in drug development and pre-registration activities to drive the program forward towards success. Your deep understanding of the R&D process, along with a commercially savvy mindset, will be crucial in navigating clinical, CMC, regulatory, and pre-clinical challenges. This role demands a leader who thrives in a fast-paced, entrepreneurial environment and possesses the ability to influence and lead multifunctional teams without direct authority.

• Lead the IMU-838 program through various stages of clinical development, ensuring alignment with strategic objectives and compliance with regulatory standards.
• Coordinate cross-functional teams, fostering collaboration and ensuring seamless integration of clinical development, regulatory affairs, compliance, GxP, and vendor management.
• Manage program budget and oversee budget impact with external suppliers and vendors.
• Drive the program with a hands-on, entrepreneurial approach, encouraging innovative thinking for problem-solving and challenging the status quo.
• Present program updates and strategies to senior management, effectively communicating program timelines, development progress and propose solutions for emerging challenges.